CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


ArgatrobanWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug859 Enoxaparin sodium Wiki 1.00
drug962 Fondapariniux Wiki 1.00
drug2595 Unfractionated heparin Wiki 0.71

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D016638 Critical Illness NIH 0.14

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19: A Prospective Randomized Study (The IMPACT Trial)

The purpose of this study is to determine if therapeutic dose anticoagulation (experimental group) improves 30-day mortality in participants with COVID-19 compared to those patients receiving the intermediate dose prophylaxis (control group). Following screening, subjects will be randomized 1:1 to intermediate dose prophylaxis or therapeutic dose anticoagulation treatment arms.Treatment will continue for 28 days, followed by a 6 month follow-up period.

NCT04406389 COVID-19 Drug: Enoxaparin sodium Drug: Unfractionated heparin Drug: Fondapariniux Drug: Argatroban
MeSH:Critical Illness

Primary Outcomes

Description: Comparison of number of COVID-19 positive patients who have died within 30 days of starting treatment on each treatment arm

Measure: 30-day mortality

Time: 30 days

Secondary Outcomes

Description: Comparison of length of ICU stay in days between each treatment arm.

Measure: Length of Intensive Care Unit (ICU) Stay in Days

Time: 6 months

Description: Comparison of number of documented VTE, arterial thrombosis and microthrombosis events on each treatment arm

Measure: Number of documented venous thromboembolism (VTE), arterial thrombosis (stroke, myocardial infarction, other) and microthrombosis events

Time: 6 months

Description: Comparison of major and clinically-relevant non-major bleeding events on each treatment arm, as defined by the International Society of Thrombosis and Haemostasis (ISTH) criteria.

Measure: Number of major and clinically relevant non-major bleeding events

Time: 6 months


No related HPO nodes (Using clinical trials)